source
- Sanofi and Regeneron deepen collaboration, adding new immunology antibody programSanofi and Regeneron announced an expanded partnership that builds on the success of their joint drug Dupixet, targeting a pipeline of experimental antibodies for immunological disorders. Under th…
- Zealand Pharma shares tumble 12% after Boehringer obesity drug trial meets endpoints but disappoints analystsA phase 3 trial of Boehringer Ingelheim's dual‑agonist drug survodutide in people with obesity and type 2 diabetes was presented at the European Association for the Study of Diabetes meeting in Mil…